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from a Young Woman with Cardiac 
angiosarcoma
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Background: Treating patients who are critically ill with radiotherapy (RT) brings a unique 
set of challenges as it involves treating patients who require mechanical life support, 
unconventional positioning, and a multidisciplinary team approach to ensure safety. 
However, when the benefits of such treatment outweigh the risks, the challenges can be 
overcome, as demonstrated in this unique case of cardiac angiosarcoma.
Case description: This is a case of a 42-year-old female with a right sided cardiac 
angiosarcoma who quickly developed cardiac tamponade and respiratory failure related 
to compression of her right heart by the tumor. She was treated with high dose single 
fraction RT initially and had a clinical response allowing further conformal RT with con-
current chemotherapy.
Discussion: Managing critically ill patients requires creativity, improvisation, and careful 
consideration of existing evidence. Although limited, the data suggest that multi-mo-
dality therapy with a combination of surgery, RT, and chemotherapy provide the best 
outcomes.
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sUMMaRY
Treating patients who are critically ill with radiotherapy (RT) brings a unique set of challenges as 
it involves treating patients who require mechanical life support, unconventional positioning, and 
a multidisciplinary team approach to ensure safety. However, when the benefits of such treatment 
outweigh the risks, the challenges can be overcome, as demonstrated in this unique case of cardiac 
angiosarcoma.
Although rare, angiosarcoma is the most common primary cardiac malignancy and the majority 
occurs within the right atrial myocardium with invasion into the pericardium (1). Thus at presen-
tation symptoms can include dyspnea, chest pain, and syncope related to pericarditis, pericardial 
effusion, and cardiac tamponade (2). Local control is important in this disease to improve these 
symptoms and prevent development of metastatic disease (3). However, in general, survival is poor 
with median survival between 12 and 36 months with multi-modality therapy (4, 5).
FIgURe 2 | (a) Mock-up of clinical setup 8 Gy × 1 Gy, based on depth and field size calculations from prior CT simulation in supine position. (B) Mock-up of DRR 
for clinical setup with GTV (red). (C) kV image of AP setup.
FIgURe 1 | (a) Magnetic resonance imaging (MRI) axial T2-weighted image demonstrating cardiac angiosarcoma. Yellow arrows pointing to tumor. RV, right 
ventricle; LV, left ventricle. (B) MRI sagittal T2-weighted image demonstrating cardiac angiosarcoma. Yellow arrows pointing to tumor. RA, right atrium; RV, right 
ventricle.
2
Fields et al. Treating the Critically Ill with RT
Frontiers in Oncology | www.frontiersin.org March 2017 | Volume 7 | Article 29
CLINICaL pReseNtatIoN
A 42-year-old female presented with progressive dyspnea and 
bilateral lower extremity edema. Chest x-ray and a computed 
tomography scan of the chest revealed pericardial effusion. 
Trans-thoracic echocardiography demonstrated echogenic mate-
rial within the effusion. During a pericardial window procedure, 
a pericardial mass adherent to the epicardium was discovered 
and biopsy confirmed cardiac angiosarcoma. Cardiac magnetic 
resonance imaging (MRI) showed a large heterogeneous mass in 
the right atrium and ventricle infiltrating the myocardium and 
pericardium (Figures 1A,B).
tReatMeNt
She was not a candidate for aggressive surgery due to her reli-
gious objection for receiving blood products. Therefore, it was 
decided to pursue concurrent chemoradiotherapy with external 
beam RT to a dose of at least 50 Gy in 25 fractions with weekly 
paclitaxel.
Several hours after initial supine simulation, she became 
dyspneic and orthopneic, necessitating intubation and ventila-
tion. Due to tumor compression of the right ventricle, she could 
not lie flat without developing symptomatic bradycardia, and the 
decision was made to try a large single fraction emergently.
Using the supine simulation CT scan, we constructed a single 
AP field based on tumor size and performed monitor unit cal-
culations to a prescription point deep to the tumor for a dose of 
8 Gy in a single fraction. We created a mock-up of this plan on 
the supine scan, but due to different patient positioning, this was 
in reality a clinical setup (Figure 2). Importantly, this could also 
have been done with a diagnostic CT or MRI if CT simulation had 
not yet been performed on the patient.
In order to at least obtain a port film in this position, with the 
couch at 90° and the gantry angled to provide an en-face photon 
AP field, the patient’s trunk needed to be flexed at 25° or less 
for the imager to clear without collision. The first attempt with 
this setup was unsuccessful because she was unable to lie at an 
angle below 45° without becoming tachypneic and hypoxic. The 
next day, the dose was successfully administered with this clinical 
FIgURe 3 | (a) Example of the patient positioning for 8 Gy fraction. The treatment couch and gantry are rotated to accommodate the patient’s inability to lie flat. 
(B) Example of extra staff and machines required in the room for daily treatments.
FIgURe 4 | Composite treatment plan showing the 8 gy × 1 gy with en-face photons plus the arc technique with the additional 50 gy in 25 fractions.
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setup (Figure  3A). This required the presence of the medical 
intensivist, cardiac ICU nurse, respiratory therapist, as well as 
the radiation oncologist, medical physicist, dosimetrist, and a 
multitude of therapists (Figure 3B).
With the large fraction RT, her symptoms improved over a 
week, allowing re-simulation while lying at a 15° angle. An arc 
plan was created for an additional 50  Gy in 25 fractions (total 
dose of 58 Gy in 26 fractions) (Figure 4). She received her first 
treatment that day and subsequently initiated her first cycle of 
paclitaxel.
By the 10th day of fractionated treatment, the patient was able 
to be treated off of the ventilator with a tracheostomy collar. With 
the tumor burden decreasing, her right heart failure resolved 
and she had a cuff-less tracheostomy placed on the 17th day and 
was breathing room air. By the completion of her treatment, the 
patient was sitting up, talking, spending time with her daughters 
and awaiting discharge to a rehabilitation facility. She was seen at 
1 month posttreatment and was without acute toxicity from the 
chemoradiation and with no clinical evidence of progression of 
disease.
DIsCUssIoN
Managing critically ill patients requires creativity, improvisation, 
and careful consideration of existing evidence. In this case report, 
we present the challenging situation of a young woman with 
cardiac angiosarcoma, a detailed assessment of our treatment 
techniques as well as a review of the published literature on this 
topic.
To date, there are several large retrospective studies 
documenting outcomes for patients with cardiac angiosarcomas 
(4, 5). However, it is difficult to evaluate outcomes based on these 
taBLe 2 | taxol-based chemotherapy in cardiac angiosarcoma.
Reference Number of pts Chemotherapy Rt surgery outcome
Minichillo et al. (13) 1 Docetaxel 35 mg/m2 weekly 54 Gy/30 fx None 2 years deceased of disease
Suderman et al. (15) 1 Docetaxel 25 mg/m2 weekly Concurrent, no 
dose specified
None 16 months deceased with NED
Hata et al. (17) 1 (with bilateral 
lung nodules at 
presentation)
Paclitaxel 60 mg/m2 and 
carboplatin AUC 2 weekly
60 Gy/30 fx Unresectable 5 months alive NED
Nakamura-Horigome 
et al. (3)
1 Docetaxel 25 mg/m2 weekly 
concurrent and adjuvant
42 Gy/21 fx None 12 months alive NED
Jang et al. (16) 1 Docetaxel 25 mg/m2 weekly 50 Gy/30 fx Initial resection 
with microscopic 
positive margins
32 months deceased of disease
Ram Prabu et al. (14) 1 (with bilateral 
lung nodules and 
pleural effusion at 
presentation)
Docetaxel 80 mg/m2 days 1, 8, 15 
q 4 weeks
None None 1 year alive NED
taBLe 1 | Radiotherapy (Rt) doses and outcomes in cardiac angiosarcoma.
Reference Number of pts Chemotherapy Rt surgery outcome
Isambert et al. (4) 100 
non-metastatic
90 patients, 90% with 
anthracycline-containing regimen
Range 10–64 Gy, median 
50 Gy in a total of 24 patients
75 patients with 
complete resection in 
13.3%
RT associated with improved 
progression-free survival
Randhawa et al. (5) 42 Most doxorubicin and ifosfamide 
total of 25 patients
15 patients, no doses 30 patients with 
complete resection in 
6 patients
Multimodal therapy improved 
survival from 14.1 to 36.5 months
Aoka et al. (6) 1 Interleukin-2 adjuvant 64 Gy/16 fx with carbon-ion RT None 1 year alive with disease
Takenaka et al. (7) 11 (sarcoma 
metastatic to 
heart from other 
sites)
3 patients (varied regimens) 25–60 Gy in 5–30 fx (in 7 
patients)
None Median OS with RT was 
10.5 months compared to 3.5 
without
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series as patients are included with varying stages of disease 
and non-uniform treatment algorithms. However, the primary 
conclusion is that combined modality therapy with the combina-
tion of surgery, chemotherapy, and RT, or the combination of 
chemotherapy and RT provide the best outcomes. Specifically, the 
addition of RT to either surgery or chemotherapy has been shown 
to improve progression-free survival (PFS) (4). The doses of RT 
used in these experiences are quite variable but have a median of 
50 Gy (range 10–64 Gy) (Table 1). Based on the data, we chose 
to use 50 Gy in 25 fractions initially and with the addition of the 
8 Gy in a single fraction ended up with 58 Gy in 26 fractions. For 
the additional 50 Gy, we used intensity modulated RT with arcs in 
order to respect the normal tissue tolerances for lung, esophagus, 
and spinal cord.
Anthracyline-based chemotherapy has been the standard for 
soft-tissue sarcoma and is the primary chemotherapy used in the 
largest reported experience of patients with cardiac angiosarcoma 
(8–10). However, anthracyclines are known for their cardiac tox-
icity, which can be exacerbated with concurrent RT (11). More 
recently, taxanes have been used in patients with angiosarcoma 
due to the radiosensitivity, high clinical response rates, and 
favorable toxicity profile (12). The Phase II ANGIOTAX study 
using paclitaxel 80 mg/m2 on days 1, 8, and 15 every 4 weeks for 
two cycles in metastatic or unresectable angiosarcoma showed 
this regimen to be well-tolerated and provide 45% PFS at 
4 months (12). This regimen has been used in primary cardiac 
angiosarcoma as well, with some long-term survivors (Table 2) 
(3, 13–16). This patient was treated with taxol 30 mg/m2 weekly 
during RT.
Despite the fact that rates of intensive care unit use is increasing 
in the United States and that malignancy is a common cause of 
airway obstruction, there is very little data on treating critically 
ill patients with RT (18–20). A retrospective study from London, 
ON, Canada, showed that of 26 patients who were intubated for 
malignant airway obstruction and treated with RT, 27% were 
successfully extubated and rates of extubation correlated with 
increased doses of RT. However, the study notes that these 26 
patients are a small fraction of all patients intubated due to malig-
nant obstruction and many may not even receive RT due to lack 
of referral, radiation oncologists’ reluctance to treat, or patient/
family preference (21). The lack of referral and radiation oncolo-
gists’ reluctance to treat may be due to the scarcity of emergent 
indications for RT, as most patients are treated as outpatients. 
The case presented here demonstrates that with good team work 
and careful planning, these treatments can be accomplished 
successfully.
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etHICs stateMeNt
This study was carried out in accordance with the recom-
mendations of the VCU IRB with written informed consent 
from the patient and her family. All subjects gave written 
informed consent in accordance with the Declaration of 
Helsinki.
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